Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Michael J. Blaha"'
Publikováno v:
American Journal of Preventive Cardiology, Vol 13, Iss , Pp 100456- (2023)
Traditionally, guidelines divide patients into primary and secondary prevention for atherosclerotic cardiovascular disease (ASCVD) risk management. However, the modern understanding of the biological progression of atherosclerosis is inconsistent wit
Externí odkaz:
https://doaj.org/article/464b2dce37b845d79ad1fa7d909730a0
Autor:
Kamal Awad, Maged Mohammed, Mahmoud Mohamed Zaki, Abdelrahman I. Abushouk, Gregory Y. H. Lip, Michael J. Blaha, Carl J. Lavie, Peter P. Toth, J. Wouter Jukema, Naveed Sattar, Maciej Banach, on behalf of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP)
Publikováno v:
BMC Medicine, Vol 19, Iss 1, Pp 1-17 (2021)
Abstract Background Current evidence from randomized controlled trials on statins for primary prevention of cardiovascular disease (CVD) in older people, especially those aged > 75 years, is still lacking. We conducted a systematic review and meta-an
Externí odkaz:
https://doaj.org/article/dbbcf8d8e15b49b5b56b0ecaba23ca1e
Autor:
Miguel Cainzos‐Achirica, Renato Quispe, Reed Mszar, Ramzi Dudum, Mahmoud Al Rifai, Raimund Erbel, Andreas Stang, Karl‐Heinz Jöckel, Nils Lehmann, Sara Schramm, Börge Schmidt, Peter P. Toth, Jamal S. Rana, Joao A. C. Lima, Henrique Doria de Vasconcellos, Donald Lloyd‐Jones, Parag H. Joshi, Colby Ayers, Amit Khera, Michael J. Blaha, Philip Greenland, Khurram Nasir
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 16 (2022)
Background The value of coronary artery calcium (CAC) in the allocation of PCSK9i (proprotein convertase subtilisin/kexin type 9 inhibitors) among individuals without clinically evident atherosclerotic cardiovascular disease (ASCVD) is unknown for in
Externí odkaz:
https://doaj.org/article/2a86dc1a2d4545368ad220f398916818
Autor:
Ellen Boakye, S.M. Iftekhar Uddin, Olufunmilayo H. Obisesan, Albert D. Osei, Omar Dzaye, Garima Sharma, John William McEvoy, Roger Blumenthal, Michael J. Blaha
Publikováno v:
American Journal of Preventive Cardiology, Vol 8, Iss , Pp 100256- (2021)
Objective: Aspirin has been widely utilized over several decades for atherosclerotic cardiovascular disease (ASCVD) prevention among adults in the United States. We examined trends in aspirin use among adults aged ≥40 years from 1998 to 2019 and as
Externí odkaz:
https://doaj.org/article/2df1ae6899e34a3fa4006d0e5707b8af
Publikováno v:
American Journal of Preventive Cardiology, Vol 5, Iss , Pp 100148- (2021)
Background: Reports have suggested decreasing attention to CVD comorbidities during the COVID-19 pandemic, despite their association with worse virus-related outcomes. Using nowcasting tools, we sought to explore temporal trends in public interest by
Externí odkaz:
https://doaj.org/article/f308fccca17e48ceb9a0f75055ff3d14
Autor:
Michael D. Miedema, Zeina A. Dardari, Sina Kianoush, Salim S. Virani, Joseph Yeboah, Thomas Knickelbine, Veit Sandfort, Carlos J. Rodriguez, Khurram Nasir, Michael J. Blaha
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 12 (2018)
Background The potential impact of the 2016 United States Preventive Services Task Force (USPSTF) guidelines on statins for primary prevention of atherosclerotic cardiovascular disease (ASCVD) warrants further analysis. Methods and Results We studied
Externí odkaz:
https://doaj.org/article/95b83e455c2d487c8169b2a839e74070
Autor:
Parag H. Joshi, Arif A. Khokhar, Joseph M. Massaro, Seth T. Lirette, Michael E. Griswold, Seth S. Martin, Michael J. Blaha, Krishnaji R. Kulkarni, Adolfo Correa, Ralph B. D'Agostino, Steven R. Jones, Peter P. Toth
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 5, Iss 5 (2016)
BackgroundRemnant lipoproteins (RLPs), the triglyceride‐enriched precursors to low‐density lipoprotein, are an emerging risk factor for coronary heart disease (CHD). We sought to determine the association of RLP cholesterol (RLP‐C) levels with
Externí odkaz:
https://doaj.org/article/8f215e1d07c849c9b00c05456b1ecbf5
Publikováno v:
Journal of Clinical Lipidology. 15:782-788
For primary prevention, statin therapy reduces the incidence of atherosclerotic cardiovascular disease (ASCVD) events in adults with intermediate or high estimated 10-year risk using traditional population-based risk calculators. While a variety of r
Autor:
J. Wouter Jukema, Peter P. Toth, Gregory Y.H. Lip, Mahmoud Mohamed Zaki, Maciej Banach, Abdelrahman Ibrahim Abushouk, Michael J. Blaha, Naveed Sattar, Maged Mohammed, Kamal Awad, Carl J. Lavie
Publikováno v:
BMC Medicine, Vol 19, Iss 1, Pp 1-17 (2021)
BMC Medicine, 19(1). BMC
BMC Medicine
BMC Medicine, 19(1). BMC
BMC Medicine
Background Current evidence from randomized controlled trials on statins for primary prevention of cardiovascular disease (CVD) in older people, especially those aged > 75 years, is still lacking. We conducted a systematic review and meta-analysis of
Autor:
Melissa A. Daubert, Michael J. Blaha
Publikováno v:
JACC: Cardiovascular Imaging. 14:2411-2413